ERCC3 serves as a prognostic biomarker for hepatocellular carcinoma and positively regulates cell proliferation and migration
This study is the first to reveal the association between high ERCC3 expression and poor prognosis in HCC and to elucidate its immunomodulatory role in HCC. Unlike previous studies, we found that ERCC3 promotes HCC progression by regulating the inflammatory microenvironment and immune checkpoints. These findings establish a novel theoretical foundation for the development of targeted immunotherapies for HCC and provide new insights into the molecular mechanisms underlying ERCC3's role in HCC.
Authors
- Jiahui Du (ORCID: https://orcid.org/0000-0003-3238-0469)
- Songbai Liu (ORCID: https://orcid.org/0000-0002-3920-1032)
- Yijie Wu (ORCID: https://orcid.org/0000-0002-7128-4595)
- Changhong Jia
- Xiuqin Qiu
- Xiaojun Wang
- Weijie Wang (ORCID: https://orcid.org/0000-0002-4509-5248)
- Cunbao Ding
- Chen Yang (ORCID: https://orcid.org/0000-0001-6011-4067)
- Chaoxu Gao
Institutions
- North China University of Science and Technology (CN)
- Soochow University (CN)
- Suzhou Vocational Health College (CN)
- The Fifth People’s Hospital of Suzhou (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s12672-025-02194-y
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52